Current Atherosclerosis Reports

, Volume 7, Issue 4, pp 263–267 | Cite as

Stroke as a complication of congenital heart disease

  • JiY Chong
  • Shunichi Homma
  • J. P. Mohr
Article

Abstract

Patent foramen ovale is a common finding in the general population. It is associated with an increased risk of stroke, but it may not have a significant effect on recurrent stroke risk in medically treated patients. Recently, many questions have arisen with respect to best treatment for preventing recurrent stroke. Some data from a clinical trial of anticoagulation compared with antiplatelet therapy support anti-platelet treatment for secondary prevention. There are not enough data currently to support surgical or percutaneous closure of patent foramen ovale for stroke prevention.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Lapostolle F, Borron SW, Surget V, et al.: Stroke associated with pulmonary embolism after air travel. Neurology 2003, 60:1983–1985.PubMedGoogle Scholar
  2. 2.
    Lethen H, Flachskampf FA, Schneider R, et al.: Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol 1997, 80:1066–1069.PubMedCrossRefGoogle Scholar
  3. 3.
    Cramer SC, Rordorf G, Maki JH, et al.: Increased pelvic vein thrombi in cryptogenic stroke. Results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) study. Stroke 2004, 35:46–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Steiner MM, Di Tullio MR, Rundek T, et al.: Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke 1998, 29:944–948.PubMedGoogle Scholar
  5. 5.
    De Castro S, Cartoni D, Fiorelli M, et al.: Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke 2000, 31:2407–2413.PubMedGoogle Scholar
  6. 6.
    Mas JL, Arquizan C, Lamy C, et al.: Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001, 345:1740–1746.PubMedCrossRefGoogle Scholar
  7. 7.
    Homma S, Sacco RL, Di Tullio MR, et al.: Atrial anatomy in non-cardioembolic stroke patients. Effect of medical therapy. J Am Coll Cardiol 2003, 42:1066–1072.PubMedCrossRefGoogle Scholar
  8. 8.
    Horton SC, Bunch TJ: Patent foramen ovale and stroke. Mayo Clin Proc 2004, 79:79–88.PubMedGoogle Scholar
  9. 9.
    Berthet K, Thomas L, Cohen A, et al.: Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 2000, 31:398–403.PubMedGoogle Scholar
  10. 10.
    Lamy C, Giannesini C, Zuber M, et al.: Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale. The PFO-ASA Study. Stroke 2002, 33:706–711.PubMedCrossRefGoogle Scholar
  11. 11.
    Bousser MG: Estrogens, migraine, and stroke. Stroke 2004, 35(Suppl 1):2652–2656.PubMedCrossRefGoogle Scholar
  12. 12.
    Hagen PT, Scholz DG, Edwards WD: Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984, 59:17–20.PubMedGoogle Scholar
  13. 13.
    Meissner I, Whisnant JP, Khandheria BK, et al.: Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: The SPARC Study. Mayo Clin Proc 1999, 74:862–869.PubMedCrossRefGoogle Scholar
  14. 14.
    Agmon Y, Khandheria BK, Meissner I, et al.: Comparison of frequency of patent foramen ovale by transesophageal echocardiography in patients with cerebral ischemic events versus in subjects in the general population. Am J Cardiol 2001, 88:330–332.PubMedCrossRefGoogle Scholar
  15. 15.
    Lechat P, Mas JL, Lascault G, et al.: Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988, 318:1148–1152.PubMedCrossRefGoogle Scholar
  16. 16.
    Cabanes L, Mas JL, Cohen A, et al.: Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 1993, 24:1865–1873.PubMedGoogle Scholar
  17. 17.
    Overell JR, Bone I, Lees KR: Interatrial septal abnormalities and stroke: A meta-analysis of case-control studies. Neurology 2000, 55:1172–1179.PubMedGoogle Scholar
  18. 18.
    Bogousslavsky J, Garazi S, Jeanrenaud X, et al.: Stroke recurrence in patients with patent foramen ovale: The Lausanne Study. Neurology 1996, 46:1301–1305.PubMedGoogle Scholar
  19. 19.
    Nedeltchev K, Arnold M, Wahl A, et al.: Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry 2002, 72:347–350.PubMedCrossRefGoogle Scholar
  20. 20.
    Homma S, Sacco RL, di Tullio MR, et al.: Effect of medical treatment in stroke patients with patent foramen ovale. Circulation 2002, 105:2625–2631.PubMedCrossRefGoogle Scholar
  21. 21.
    Homma S, Di Tullio MR, Sacco RL, et al.: Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. Stroke 2004, 35:2145–2149.PubMedCrossRefGoogle Scholar
  22. 22.
    Messe SR, Silverman IE, Kizer JR, et al.: Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm. Neurology 2004, 62:1042–1050.PubMedGoogle Scholar
  23. 23.
    Homma S, Di Tullio MR, Sacco RL, et al.: Surgical closure of patent foramen ovale in cryptogenic stroke patients. Stroke 1997, 28:2376–2381.PubMedGoogle Scholar
  24. 24.
    Devuyst G, Bogousslavsky J, Ruchat P, et al.: Prognosis after stroke followed by surgical closure of patent foramen ovale: a prospective follow-up study with brain MRI and simultaneous transesophageal and transcranial Doppler ultrasound. Neurology 1996, 47:1162–1166.PubMedGoogle Scholar
  25. 25.
    Bruch L, Parsi A, Grad MO, et al.: Transcatheter closure of interatrial communications for secondary prevention of paradoxical embolism. Single-center experience. Circulation 2002, 105:2845–2848.PubMedCrossRefGoogle Scholar
  26. 26.
    Windecker S, Wahl A, Nedeltchev K, et al.: Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol 2004, 44:750–758.PubMedCrossRefGoogle Scholar
  27. 27.
    Khairy P, O’Donnell CP, Landzberg MJ: Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli. Ann Intern Med 2003, 139:753–760.PubMedGoogle Scholar
  28. 28.
    Anzola GP, Morandi E, Casilli F, Onorato E: Does transcatheter closure of patent foramen ovale really “Shut the Door?” A prospective study with transcranial Doppler. Stroke 2004, 35:2140–2144.PubMedCrossRefGoogle Scholar
  29. 29.
    Krumsdorf U, Ostermayer S, Billinger K, et al.: Incidence and clinical course of thrombus formation on atrial septal defect and patent foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004, 43:302–309.PubMedCrossRefGoogle Scholar
  30. 30.
    Martin F, Sanchez P, Doherty E, et al.: Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation 2002, 106:1121–1126.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • JiY Chong
    • 1
  • Shunichi Homma
    • 1
  • J. P. Mohr
    • 1
  1. 1.Doris and Stanley Tananbaum Stroke Center, Neurological InstituteColumbia University Medical CenterNew YorkUSA

Personalised recommendations